Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Resveratrol

What does the research say about Resveratrol?

6 health outcomes synthesised

Resveratrol is a plant-derived compound studied for its potential effects on metabolic and cardiovascular health markers. The research syntheses cover 6 health outcomes, with the strongest evidence emerging for reduced triglyceride levels, where two of four studies reported beneficial effects in clinical populations, though the results across trials are mixed. Doses studied for antioxidant-related outcomes converge around 400-800 mg/day, primarily in populations with type 2 diabetes or other conditions involving oxidative stress.

Strongest evidence The evidence base for resveratrol is modest overall. The outcome with the highest evidence strength is reduced triglyceride levels (moderate strength), based on 4 studies. Two studies reported beneficial effects (small to moderate effect size), while two found neutral effects. The beneficial findings came from meta-analyses and systematic reviews in postmenopausal women and type 2 diabetes patients, but many individual studies did not reach statistical significance, and effect size remains mixed.

Mixed or weaker evidence All other outcomes — reduced blood cholesterol (4 studies), improved insulin sensitivity (3 studies), reduced low-density lipoprotein level (3 studies), increased antioxidant enzyme levels (3 studies), and increased total serum antioxidant capacity (3 studies) — carry a low evidence strength. For blood cholesterol, only 1 of 4 studies found a benefit; the other three reported neutral effects. Improved insulin sensitivity showed a small effect in 1 of 3 studies, with the remainder neutral. Total serum antioxidant capacity was the only outcome with all 3 studies reporting beneficial effects (moderate effect size), but this is based on a small number of trials in clinical populations with elevated oxidative stress.

Effective dose patterns Two outcomes — increased antioxidant enzyme levels and increased total serum antioxidant capacity — both pointed to a typical dose range of 400-800 mg/day, with study durations of 8-12 weeks (median 72 days). Other outcomes did not report consistent dose ranges, limiting direct cross-outcome dose comparisons.

Population insights The majority of evidence comes from clinical populations: type 2 diabetes mellitus, postmenopausal women with insulin resistance, metabolic dysfunction-associated steatotic liver disease, polycystic ovary syndrome, and head and neck cancer patients receiving home enteral nutrition. The generalizability to healthy individuals remains uncertain, especially for antioxidant-related outcomes where baseline oxidative stress may influence the magnitude of effect.

Notable caveats Every synthesis flagged small sample sizes (only 3-4 studies per outcome) and preliminary conclusions. Statistical significance was inconsistent across studies, with many neutral results despite a beneficial trend. Doses and supplement forms were not consistently reported across studies on triglycerides, cholesterol, or insulin sensitivity. Publication bias is a concern for the antioxidant capacity outcome, where null studies may be underrepresented in the literature.

Frequently asked

  • What is Resveratrol good for according to research?
    Research on resveratrol has examined 6 health outcomes, primarily in metabolic and cardiovascular health. The strongest evidence (moderate strength) suggests it may reduce triglyceride levels, though only 2 of 4 studies found a benefit and effects were mixed. For antioxidant capacity, all 3 studies reported moderate beneficial effects, but this evidence is considered low strength and limited to clinical populations.
  • What dose of Resveratrol is typically used in studies?
    The most consistent dose information comes from two antioxidant-related outcomes — increased antioxidant enzyme levels and increased total serum antioxidant capacity — where studies used 400-800 mg per day over 8 to 12 weeks (median 72 days). For other outcomes like triglycerides or cholesterol, doses were not consistently reported across the included studies.
  • Who benefits most from Resveratrol?
    The research is almost entirely in clinical populations, including people with type 2 diabetes, postmenopausal women with insulin resistance, patients with metabolic fatty liver disease, and those with head and neck cancer receiving enteral nutrition. Whether healthy individuals experience similar effects is not established by the current evidence.
  • Does Resveratrol help reduce cholesterol?
    Evidence is limited. Across 4 studies, only 1 reported a beneficial effect on total blood cholesterol (small effect), and the other 3 found no significant reduction. A 2025 meta-analysis of 7 RCTs found no significant decreases in total cholesterol or LDL-C. The overall evidence strength is low.
  • What are the main limitations of research on Resveratrol?
    All six outcome syntheses are based on small numbers of studies (3-4 each), making conclusions preliminary. Many individual studies did not reach statistical significance, and results were inconsistent across trials for most outcomes. Publication bias is a concern, especially for antioxidant effects, where positive results may be overrepresented. Doses and supplement forms were often not reported, limiting comparability.
  • Is the evidence for Resveratrol's antioxidant effects strong?
    No — while total serum antioxidant capacity showed consistent beneficial effects in all 3 studies, the evidence strength is low due to the small number of studies and potential publication bias. All participants had conditions associated with elevated oxidative stress, so results may not apply to generally healthy people.

Safety profile

5 studies reporting safety data

Across 5 clinical studies, resveratrol was consistently described as well tolerated, with no specific adverse events quantitatively reported or found to be significantly different from control. Two studies explicitly noted minimal or mild adverse events, and one mentioned an overall tolerable safety profile. The evidence base is limited to these studies, which primarily focused on efficacy endpoints, and heterogeneity in outcomes was noted.

Caveats: Limited evidence base; absence of reports does not establish safety. Most studies were likely powered for efficacy, not safety, so rare adverse events may not be detected.

Most-studied combinations with Resveratrol

most supplement research is combination research
Also studied with:Turmeric (5), Ginkgo (2), Thistle (2), Vitamin D (2), Vitamin E (2), green tea (2)

  • Super Pill No. 2

    By Dragon Herbs

    4.7 (39 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $99.00
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out
Back to top